mayo 2017 Archives

‘Keratinocyte cancer’ is now the preferred term for the most commonly identified skin cancers basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which were previously commonly categorised as non-melanoma skin cancers (NMSC). Keratinocyte cancer (KC) represents about 95% of malignant skin tumours. Lifestyle changes have led to increased exposure to the sun, which has, in turn, led to a significant increase of new cases of KC, with a worldwide annual incidence of between 3% and 8%. The successful use of preventive measures could mean a significant reduction in the resources used by health systems, compared with the high cost of the treatment of these conditions. At present, there is no information about the quality of the evidence for the use of these sun protection strategies with an assessment of their benefits and risks.

Ver más

El acné es una enfermedad inflamatoria crónica que conlleva una serie de efectos psicosociales que pueden afectar en gran medida la calidad de vida del paciente. Existen distintas escalas de clasificación de gravedad del acné y otros tantos algoritmos de tratamiento, sin que haya consenso sobre la escala y guía de manejo que seguir. Por ello, un grupo de expertos españoles se reúnen para consensuar por votación la forma más apropiada de clasificar el acné y el tratamiento según la gravedad del mismo. El acné se clasifica como acné comedoniano, acné papulopustuloso leve o moderado , acné papulopustuloso grave o nodular moderado y acné grave noduloquístico o con tendencia a desarrollar cicatrices. Se consensuaron una primera y una segunda opción de tratamiento para cada grado de gravedad y un tratamiento de mantenimiento. Se efectuaron recomendaciones específicas con relación al uso combinado de antibióticos (a partir de grado papulopustuloso leve o moderado), siempre en combinación con retinoides y/o peróxido de benzoilo (POB), y el uso de isotretinoína a partir del grado papulopustuloso grave o nodular moderado.

 

Ver más

Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.
Psoriasis is a chronic cutaneous inflammatory disease. The immunopathogenesis is a com-plex interplay between T cells, dendritic cells and the epidermis in which T cells and dendritic cells maintain  skin inflammation. Anti-tumour necrosis factor (anti-TNF)-α agents have been approved for therapeutic use across a range of inflammatory disorders including psoriasis, but the anti-inflammatory mechanisms of anti-TNF-α in lesional psoriatic skin are not fully understood. We investigated early events in skin from psoriasis patients after treatment with anti-TNF-α antibodies by use of bioinformatic s tools.